Literature DB >> 33735214

Imaging-guided radiofrequency ablation of osteoid osteoma in typical and atypical sites: Long term follow up.

Francesco Somma1, Vincenzo Stoia1, Roberto D'Angelo1, Francesco Fiore1.   

Abstract

PURPOSE: To assess efficacy and safety of imaging-guided radiofrequency ablation (RFA) of Osteoid Osteoma (OO) in both typical and atypical sites. METHODS AND MATERIALS: Between January 2014 and March 2019, 102 consecutive percutaneous RFA were performed and retrospectively reviewed. The procedures were performed using a RFA bipolar ablation system (Covidien, exposed tip of 0.7-1cm), under Computed Tomography (CT) guidance or using a navigation system (Masmec) under CT and Cone Beam CT (CBCT) guidance. Patients were followed up over 24 months. Clinical success and recurrences were considered on the base of established criteria. In patients with clinical failure and/or imaging evidence of relapse, retreatment was considered.
RESULTS: Administered power per-procedure was ≤8 W (mean temperature, 90°C). The pre-procedure average value of visual analog scale (VAS) was 8.33+/-0.91. Primary and secondary success rate 96.08% (98/102) and100% (102/102), respectively. No major complication was described. Technical success was proved in every patient by CT scan acquisition after needle positioning. Relapse and tumour location were significantly correlated (p-value = 0.0165). The mean dose-length product was 751.55 mGycm2. Advanced bone healing was noted in 68 lesions after 1y-follow up and in 86 lesions after 2y-follow up.
CONCLUSION: Imaging-guided percutaneous RFA is a highly effective technique for OO, both in typical and atypical sites. CT or CBCT guidance, navigation systems and operator experience grant the technical success, which is the most crucial parameter affecting outcome.

Entities:  

Year:  2021        PMID: 33735214      PMCID: PMC7971862          DOI: 10.1371/journal.pone.0248589

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  35 in total

1.  CT-guided radiofrequency ablation of osteoid osteoma and osteoblastoma: clinical success and long-term follow up in 77 patients.

Authors:  Christoph Rehnitz; Simon David Sprengel; Burkhard Lehner; Karl Ludwig; Georg Omlor; Christian Merle; Hans-Ulrich Kauczor; Volker Ewerbeck; Marc-André Weber
Journal:  Eur J Radiol       Date:  2012-07-06       Impact factor: 3.528

Review 2.  Percutaneous Treatments of Benign Bone Tumors.

Authors:  Guillaume Koch; Roberto Luigi Cazzato; Andrew Gilkison; Jean Caudrelier; Julien Garnon; Afshin Gangi
Journal:  Semin Intervent Radiol       Date:  2018-11-05       Impact factor: 1.513

3.  Interstitial laser photocoagulation of osteoid osteomas with use of CT guidance.

Authors:  A Gangi; J L Dietemann; B Gasser; R Mortazavi; P Brunner; M Y Mourou; J C Dosch; J Durckel; J Marescaux; C Roy
Journal:  Radiology       Date:  1997-06       Impact factor: 11.105

4.  Radiologic diagnosis of osteoid osteoma: from simple to challenging findings.

Authors:  Jee Won Chai; Sung Hwan Hong; Ja-Young Choi; Young Hwan Koh; Joon Woo Lee; Jung-Ah Choi; Heung Sik Kang
Journal:  Radiographics       Date:  2010-05       Impact factor: 5.333

5.  Osteoid osteoma: percutaneous treatment with radiofrequency energy.

Authors:  Daniel I Rosenthal; Francis J Hornicek; Martin Torriani; Mark C Gebhardt; Henry J Mankin
Journal:  Radiology       Date:  2003-08-27       Impact factor: 11.105

6.  Percutaneous radiofrequency coagulation of osteoid osteoma compared with operative treatment.

Authors:  D I Rosenthal; F J Hornicek; M W Wolfe; L C Jennings; M C Gebhardt; H J Mankin
Journal:  J Bone Joint Surg Am       Date:  1998-06       Impact factor: 5.284

7.  Radiofrequency ablation of osteoid osteomas: analgesia and patient satisfaction in long-term follow-up.

Authors:  B Gebauer; F Collettini; C Bruger; K-D Schaser; I Melcher; P-U Tunn; F Streitparth
Journal:  Rofo       Date:  2013-10

Review 8.  Osteoid osteoma: multimodality imaging with focus on hybrid imaging.

Authors:  Ujwal Bhure; Justus E Roos; Klaus Strobel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-19       Impact factor: 9.236

9.  Targetability of osteoid osteomas and bone metastases by MR-guided high intensity focused ultrasound (MRgHIFU).

Authors:  Fabrice Bing; Jonathan Vappou; Michel de Mathelin; Afshin Gangi
Journal:  Int J Hyperthermia       Date:  2018-09-13       Impact factor: 3.914

10.  Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival.

Authors:  Francesco Somma; Vincenzo Stoia; Nicola Serra; Roberto D'Angelo; Gianluca Gatta; Francesco Fiore
Journal:  PLoS One       Date:  2019-05-29       Impact factor: 3.240

View more
  4 in total

1.  COVID-19 and low back pain: previous infections lengthen recovery time after intradiscal ozone therapy in patients with herniated lumbar disc.

Authors:  Francesco Somma; Alberto Negro; Vincenzo D'Agostino; Valeria Piscitelli; Gianvito Pace; Mario Tortora; Fabio Tortora; Gianluca Gatta; Ferdinando Caranci
Journal:  Radiol Med       Date:  2022-05-10       Impact factor: 6.313

2.  Radiation exposure and clinical outcome in patients undergoing percutaneous intradiscal ozone therapy for disc herniation: Fluoroscopic versus conventional CT guidance.

Authors:  Francesco Somma; Vincenzo D'Agostino; Alberto Negro; Valeria Piscitelli; Stefania Tamburrini; Carmine Sicignano; Fabrizio Fasano; Silvio Peluso; Alessandro Villa; Gianvito Pace; Giuseppe Sarti; Giuseppe Maria Ernesto La Tessa; Giovanna Pezzullo; Gianluca Gatta; Ferdinando Caranci
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.240

3.  The surgical management of osteoid osteoma: A systematic review.

Authors:  Man Shu; Jin Ke
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

4.  Cone beam computed tomography (CBCT) guidance is helpful in reducing dose exposure to pediatric patients undergoing radiofrequency ablation of osteoid osteoma.

Authors:  Francesco Fiore; Francesco Somma; Roberto D'Angelo; Luca Tarotto; Vincenzo Stoia
Journal:  Radiol Med       Date:  2021-12-27       Impact factor: 3.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.